RESUMEN
Immune-inflammatory (autoimmune and autoinflammatory) rheumatic diseases are widespread severe chronic inflammatory diseases and also "models" for studying the fundamental mechanisms of pathogenesis and approach to pharmacotherapy of other diseases associated with autoimmunity and/or autoinflammation. Uncontrolled inflammation leading to hypercoagulation forms the basis of "thromboinflammation", which is considered a universal pathogenetic mechanism of organ involvement in immune-inflammatory rheumatic diseases, as well as in COVID-19 and atherosclerotic vascular lesions (atherothrombosis). Thrombo-inflammatory mechanisms play a crucial role in systemic lupus erythematosus and antiphospholipid syndrome. Russian rheumatology, under the leadership of academician Valentina Alexandrovna Nasonova, greatly contributed to the research of these disorders. This article addresses the current view about the overlapping pathogenetic mechanisms of thrombosis in systemic lupus erythematosus and antiphospholipid syndrome, the relevance of these studies during the COVID-19 pandemic, and the prospects for antithrombotic and anti-inflammatory therapy.
Asunto(s)
Síndrome Antifosfolípido , COVID-19 , Lupus Eritematoso Sistémico , Enfermedades Reumáticas , Humanos , Síndrome Antifosfolípido/complicaciones , Síndrome Antifosfolípido/diagnóstico , Pandemias , Lupus Eritematoso Sistémico/complicaciones , Lupus Eritematoso Sistémico/tratamiento farmacológico , Autoinmunidad , Enfermedades Reumáticas/complicaciones , COVID-19/complicacionesRESUMEN
Mechanisms of action, clinical efficacy and safety of superhigh doses of methylprednisolone (pulse-therapy) in patients with SLE, RA, systemic vasculitis, Sjogren's disease are outlined.
Asunto(s)
Antiinflamatorios/administración & dosificación , Glucocorticoides/administración & dosificación , Metilprednisolona/administración & dosificación , Enfermedades Reumáticas/tratamiento farmacológico , Antiinflamatorios/efectos adversos , Glucocorticoides/efectos adversos , Humanos , Metilprednisolona/efectos adversos , Quimioterapia por Pulso , Enfermedades Reumáticas/fisiopatologíaRESUMEN
Patients with systemic juvenile rheumatoid arthritis (JRA) are often poorly responsive to existing therapeutic modalities. We evaluated the effectiveness of pulse therapy consisting of methylprednisolone 30 mg/kg/day for 3 consecutive days combined with cyclophosphamide 0.4 g/m2 body surface area on the 3rd day, for 18 patients with definite systemic JRA, who were enrolled in an open trial of 12 months' duration. The children received pulse therapy every 3 months; oral methotrexate 10 mg/m2 was started after the first pulse. A rapid and clinically significant suppression of systemic and articular manifestations was seen in all patients. Significant decreases in laboratory indices of disease activity were also observed. Side effects were minor and reversible. The results of our preliminary trial support the development of a controlled study to evaluate the efficacy of pulse therapy in systemic JRA.